Tango Therapeutics to present cancer drug combo data at ESMO 2026

Go back to Tango Therapeutics to present cancer drug combo data at ESMO 2026

Tango Therapeutics to Present Updated Vopimetostat + RAS(ON) Combination Data at European Society For Medical Oncology (ESMO) Congress 2026

October 16, 2026 7:00 AM EDT

Company to host PDAC focused investor webcast on Friday, October 23, 2026, 7:30 am ET

BOSTON, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that the Company will present updated data from a Phase 1/2 study of vopimetostat in combination with daraxonrasib or zoldonrasib in patients with MTAP deleted RAS mutant (MTAPdel/RASmut) metastatic pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) at the European Society For Medical Oncology (ESMO) Congress 2026,... More